RxDoctor Payments Data

Eric Sorensen, MD

Family Medicine · Hanford, CANPI 1063521896

Payments from drug & device makers

$4,928in general payments, 2019–2025

Across 285 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$442
  • Boehringer Ingelheim$420
  • AbbVie$414
  • Amarin Pharma, Inc.$374
  • Lilly USA, LLC$346
  • Amgen$263
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$4,83198%
  • Education$972%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,928 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$558,365
Medicare patients
3,045
Services billed
9,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide71$90,421
RexultiBrexpiprazole21$41,039
EliquisApixaban47$41,023
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$34,921
MounjaroTirzepatide28$30,350
JanuviaSitagliptin Phosphate19$27,747
JardianceEmpagliflozin21$25,256
TrulicityDulaglutide17$16,953
Janumet XrSitagliptin Phos/Metformin Hcl21$14,579
LinzessLinaclotide11$13,900
VascepaIcosapent Ethyl18$11,831
TrintellixVortioxetine Hydrobromide15$11,522
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog17$10,870
TradjentaLinagliptin11$10,418
Lantus SolostarInsulin Glargine,hum.Rec.Anlog47$8,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$442$90,42171 claims
Lilly USA, LLCMounjaro, Trulicity$346$47,30345 claims
Otsuka America Pharmaceutical, Inc.Rexulti$33$41,03921 claims
PfizerEliquis$200$41,02347 claims
Boehringer IngelheimJardiance, Tradjenta$420$35,67532 claims
GSKTrelegy Ellipta$218$34,92134 claims
AbbVieLinzess$414$13,90011 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$84$11,52215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Hanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →